Advanced carotid plaque imaging evaluates plaque biology, helping clinicians identify stroke risk more accurately, personalize treatment decisions, and improve prevention beyond stenosis measurement alone.

A novel smart device for heart failure decongestion uses pressure-guided fluid redistribution to reduce congestion, potentially improving symptoms, lowering hospitalizations, and enabling remote monitoring.

Metabolomic profiling is emerging as a promising tool for predicting asthma exacerbations, enabling earlier risk identification, personalized treatment strategies, and potentially reducing hospitalizations through proactive disease management.

ECAP-guided spinal cord stimulation enables real-time, adaptive pain management, offering more consistent symptom relief and reducing reliance on opioids for chronic pain patients.

Emerging obesity treatments may deliver both weight-loss and cardiovascular benefits, offering new options to reduce heart disease risk while addressing the growing obesity epidemic.

Retinal imaging may offer a noninvasive way to detect early Alzheimer’s-related brain changes, supporting earlier screening, risk assessment, and referral before significant cognitive decline occurs.

A 24-year U.S. analysis shows gene-targeted therapies dramatically reduced childhood spinal muscular atrophy mortality, transforming a once-fatal disease into a manageable long-term condition.

ASCO 2026 data suggest first-line talazoparib plus enzalutamide significantly delays progression in HRR-mutated metastatic prostate cancer, highlighting the growing importance of early genomic testing and biomarker-driven treatment.

A landmark study found the APOE ε4 gene was not linked to vascular brain injury progression in American Indians, highlighting the importance of cardiometabolic risk management.

The RADIOS consortium studies immune-related side effects of cancer immunotherapy, helping researchers improve treatment safety, personalize care, and optimize outcomes for patients receiving checkpoint inhibitors.